Immunohistochemistry was similar to that of intracranial meningiomas, and most of them were Vimentin (+) and EMA (+), which were generally regarded as benign tumors, but clear meningiomas are WHO II, which are invasive, and have a high probability of recurrence.[7] Butscheidt et al[4] showed that 91% of intraosseous meningiomas were WHO I, as was the case here. This evidence concerns the gene VIM and benign neoplasm.